University Medical Center Hamburg-Eppendorf
- Address
- Martinistrasse 52, Eppendorf, 20246 Hamburg, Germany
Oncology and Hematologic Malignancies
At University Medical Center Hamburg-Eppendorf, a major share of research focuses on oncology and hematologic malignancies, including leukemia, lymphoma, multiple myeloma, and a wide range of solid tumors. These studies are designed to test new treatment approaches, improve response rates, and better match therapy to tumor biology.
- Acute and chronic leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia
- Lymphomas, such as diffuse large B-cell lymphoma, mantle cell lymphoma, and Hodgkin lymphoma
- Breast cancer, prostate cancer, lung cancer, and other advanced solid tumors
- Trials evaluating new immunotherapies, targeted treatments, and combination strategies
The site is especially active in studies aiming to improve survival for difficult-to-treat cancers and to refine treatment selection for patients with advanced or relapsed disease.
Immunology, Autoimmune Disease, and Transplantation
Research in immunology and transplant medicine covers conditions where the immune system is overactive, misdirected, or needs careful control after transplantation. The trials explore better ways to manage rejection, reduce inflammation, and relieve symptoms in chronic immune-mediated diseases.
- Kidney transplant and solid organ transplantation, including rejection-related complications
- Autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s syndrome
- Inflammatory conditions including ulcerative colitis, psoriasis, and atopic dermatitis
- Studies testing immune-modulating therapies and approaches to improve long-term disease control
This portfolio reflects a strong interest in balancing effective immune suppression with safety, particularly in patients who require long-term treatment.
Cardiology, Vascular Medicine, and Critical Care
The Klinik für Intensivmedizin contributes to research in cardiovascular disease, heart failure, atrial fibrillation, and vascular disease, alongside studies in critical illness. These trials aim to improve prevention, diagnosis, and treatment outcomes in patients with serious heart and circulation problems.
- Heart failure, myocardial infarction, and cardiomyopathy
- Atrial fibrillation, aortic stenosis, and other cardiac rhythm or valve disorders
- Stroke, thrombosis, and vascular disease
- Intensive care research on severe infection, shock, and recovery after major illness
Across these studies, the goal is often to reduce complications and improve survival in high-risk patients treated at University Medical Center Hamburg-Eppendorf.
Nephrology, Urology, and Kidney Transplant Research
A substantial research area covers kidney disease, proteinuric glomerular disorders, kidney transplantation, and related urinary conditions. The trials are focused on slowing disease progression, protecting kidney function, and improving outcomes after transplant.
- Chronic kidney disease, acute kidney injury, and proteinuria
- Focal segmental glomerulosclerosis, IgA nephropathy, and other glomerular diseases
- Kidney transplant rejection and post-transplant immune complications
- Studies evaluating treatments that preserve kidney function and reduce long-term complications
This field includes both adult and pediatric research, reflecting a broad interest in renal health across age groups.
Neurology, Neurosurgery, and Mental Health
The site also supports research in neurological disorders and mental health, including conditions that affect movement, cognition, and brain function. These trials commonly aim to improve symptom control, functional outcomes, or recovery after neurological injury.
- Stroke, multiple sclerosis, and epilepsy-related or other central nervous system disorders
- Glioblastoma, medulloblastoma, and other brain tumors
- Posttraumatic stress disorder and treatment-resistant depression
- Research on symptom relief, disease progression, and quality of life
These studies combine clinical care with efforts to better understand how neurological and psychiatric conditions can be treated more effectively.
Pediatric and Rare Disease Research
Pediatric and rare disease studies form another important part of the research program, with attention to genetic disorders, rare metabolic diseases, and childhood cancers. The aim is often to improve long-term outcomes in conditions with limited treatment options.
- Children’s cancers such as acute lymphoblastic leukemia, neuroblastoma, and sarcomas
- Rare inherited disorders including Fabry disease, mucopolysaccharidoses, and phenylketonuria
- Developmental and neuromuscular diseases such as Duchenne muscular dystrophy and spinal muscular atrophy
- Trials designed to test new therapies and support better disease management in children
This area highlights the center’s role in research for rare, complex, and often lifelong conditions requiring specialized care.
Pulmonary, Infectious, and Inflammatory Diseases
Research in respiratory medicine, infectious disease, and systemic inflammation addresses both chronic and acute conditions. The studies look at ways to improve treatment for infections, lung fibrosis, and other inflammatory disorders that can seriously affect breathing and overall health.
- Idiopathic pulmonary fibrosis and other progressive lung diseases
- COVID-19, sepsis, and bacterial or viral infections
- Chronic hepatitis, primary sclerosing cholangitis, and other inflammatory organ diseases
- Trials focused on improving treatment effectiveness, symptom control, and prevention of disease progression
The research profile shows a strong interest in conditions where inflammation, infection, and organ damage intersect.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 34 therapeutic areas and 15 of 737 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 699 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 169 by active trials.
- 1AstraZeneca AB15active
lock +168 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC29trials
lock +97 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Medical Center Hamburg-Eppendorf
lock Showing 1 of 595 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 737 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 42 | Unknown | 2016-02-19 | 2026-04-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
